Novo Nordisk에 대한 매도 수량은 투자자에게 Novo Nordisk의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Novo Nordisk (NYSE:NVO) 주식, 공매도 수량 보고

Novo Nordisk

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

News

Politics

Markets

Tech

PLTR

PYPL

목요일(6일) 억만장자 기업가 마크 큐반(Mark Cuban)은 일론 머스크의 의도와 표현의 자유에 대한 그의 통제에 의문을 제기하며, 기술 거물 일론 머스크가 정부에 미치는 영향력에 대한 논쟁을 불러일으켰다.

마크 큐반, 트럼프 행정부에서 커지는 일론 머스크의 영향력 지적

도널드 트럼프의 그린란드 장악을 위한 새로운 움직임은 작지만 놀랍도록 큰 경제력을 가진 덴마크와의 치열한 대결을 불러일으키고 있다. 덴마크는 미국에 맞설 만한 군사력은 없지만, 수백만 명 미국인이 매일 사용하는 주요 제품을 통제할 수 있는 강력한 힘이 있다. 

덴마크, 그린란드 노리는 트럼프에 대응해 오젬픽·위고비 공급 차단할 수도

Biotech

Health Care

Technicals

Previews

Trading Ideas

General

노보 노디스크 A/S(NYSE:NVO)는 수요일 시장 개장 전에 4분기 실적을 발표할 예정이다. 월스트리트는 주당순이익(EPS)이 86센트, 매출이 114억 달러에 이를 것으로 예상하고 있다. 주가는 지난 1년 동안 30.14% 하락했으며, 연초 대비 5.60% 하락했다.

4분기 실적 발표 전 노보 노디스크 주가 하락: 분석가들은 여전히 68% 상승 가능성을 주목

Novo Nordisk AS

Precidian ETFs Trust Novo Nordisk A/S B Shares ADRhedged

Novo Resources Corp Warrants (27/08/2023)

NOVO INTEGRATED SCIENCES by Novo Integrated Sciences, Inc.

Novo Integrated Sciences Inc

Tidal Trust II Defiance Daily Target 2X Long NVO ETF

Novo Nordisk expects Mim8 regulatory submission during 2025. Data from the ongoing phase 3 FRONTIER programme will be disclosed at upcoming congresses and in publications in 2025 and 2026.
 &nbsp;

Large Cap

Novo Nordisk Announced Interim Results From Phase 3 FRONTIER3 Trial Of Mim8 In Children With Hemophilia A With And Without Inhibitors, Showed That 74.3% Of Children On Once-weekly Mim8 Prophylaxis Experienced Zero Treated Bleeds

Billionaire entrepreneur Mark Cuban on Thursday raised questions about Elon Musk&#8216;s intentions and his control over free speech, stirring a debate on the tech mogul&#8217;s influence on the government.
What Happened: On Thursday, Cuban, the minority owner of the Dallas Mavericks, took to X to express his concerns about Musk&#8217;s motivations and his control over free speech. 
He tweeted, &#8220;Anyone consider that maybe Elon's mission, is for Elon to get what he wants, rather than the country to get what you voted for?&#8221; 
He added, &#8220;The censorship of the platform you adore is in the hands of a single person, who is on a mission to make himself the most powerful person in the world. above and beyond the President of the United States.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Anyone consider that maybe Elon's mission, is for Elon to get what he wants, rather than the country to get what you voted for ? It's not a shock for Elon , or anyone, to put their personal goals first Elon seems to be on a mission to protect brand Elon at all costs. No ?…
&mdash; Mark Cuban (@mcuban) <a href="https://twitter.com/mcuban/status/1887526743541494092?ref_src=twsrc%5Etfw">February 6, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Cuban&#8217;s remarks follow Musk&#8217;s increasing influence under President Donald Trump and the sweeping changes he is driving through the DOGE, which has<a href="https://in.benzinga.com/markets/cryptocurrency/25/02/43460243/market-skeptical-of-doge-hype-questions-elon-musks-execution-bernstein-says"> faced skepticism from some critics.</a>
SEE ALSO: <a href="https://www.benzinga.com/news/legal/25/02/43539572/musk-allies-face-treasury-data-limits-as-judge-steps-in">Musk Allies Face Treasury Data Limits As Judge Steps In</a>
Why It Matters: Cuban&#8217;s comments add to the growing debate around Musk&#8217;s influence and his role in shaping policies. Reid Hoffman, the co-founder of LinkedIn Corporation and former COO of PayPal Holdings, has <a href="https://www.benzinga.com/politics/25/02/43548753/reid-hoffman-rebuffs-elon-musks-doge-theres-a-reason-the-government-doesnt-work-like-companies">previously criticized Musk&#8217;s decision-making</a>, suggesting that his &#8216;move fast and break things&#8217; approach should be more compassionate and judicious in the government context.
Furthermore, Musk&#8217;s Department of Government Efficiency, (DOGE), has <a href="https://www.benzinga.com/general/health-care/25/02/43520715/novo-nordisk-opposes-government-price-setting-as-elon-musks-doge-gains-access-to-cms-amid-bernie-sanders-criticism">recently gained access to the</a> Centers for Medicare and Medicaid Services (CMS), which has raised concerns about potential challenges for pharmaceutical companies. Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), a Danish pharmaceutical giant, is among those that could be affected by this move.
However, Alex Karp, The CEO of Palantir Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) <a href="https://www.benzinga.com/25/02/43487682/palantir-ceo-hails-elon-musks-doge-initiative-anticipates-positive-outcome">considers DOGE as &#8220;a revolution</a>&#8221; and a positive disruptor. &#8220;There will be ups and downs. There&#8217;s a revolution. Some people are going to get their heads cut off. We&#8217;re expecting to see really unexpected things and to win,&#8221; stated Karp.
<ul>
<li>READ MORE: <a href="https://www.benzinga.com/25/02/43552235/tesla-hikes-model-x-price-by-5000-making-it-more-expensive-than-cybertruck">Tesla Hikes Model X Price By $5000, Making It More Expensive Than Cybertruck</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Mark Cuban Calls Out Elon Musk's Growing Influence Under Trump: 'On A Mission To Make Himself...Above And Beyond The President Of The United States'

Donald Trump's renewed push to <a href="https://www.benzinga.com/markets/emerging-markets/25/01/43133508/trump-wants-to-buy-greenland-for-us-security">take control of Greenland</a> is setting off a high-stakes showdown with Denmark, a small country with surprisingly big economic power. While Denmark might not have a military capable of standing up to the U.S., it has something just as powerful—control over key products that millions of Americans rely on every day.
<h2 class="wp-block-heading">Trump's Greenland Obsession and Trade War Threats</h2>
Trump has long wanted to bring Greenland under U.S. control, arguing it's <a href="https://www.benzinga.com/startups/25/01/43074027/why-trump-sees-greenland-as-a-2-billion-security-deal">vital for national security</a>.&nbsp;
"I'm talking about protecting the free world. You look at; you don't even need binoculars; you look outside," he said last month. "You have China ships all over the place. You have Russian ships all over the place. We're not letting that happen."
Don't Miss:
<ul>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a></li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
</ul>
Vice President JD Vance recently said that Trump &#8220;doesn&#8217;t care what Europeans scream at us&#8221; and refused to rule out the use of military force.&nbsp;
Trump's latest strategy? Tariffs. He recently threatened to impose a 25% duty on all imports from Mexico and most from Canada, along with a 10% tariff on Chinese goods. He hinted that Denmark could be next if it refuses to give up Greenland.
Denmark's response? A firm &#8220;No&#8221; backed by European allies. Greenland's prime minister made it clear: "Greenland belongs to the people of Greenland." But Denmark isn't just pushing back with words. It has economic weapons that could cause immediate pain for U.S. consumers.
Trending: Nancy Pelosi Invested $5 Million In An AI Company Last Year — <a href="https://www.benzinga.com/money/elf-labs-nancy-pelosi">Here's How You Can Invest In Multiple Pre-IPO AI Startups With Just $1,000</a>
<h2 class="wp-block-heading">Denmark's Secret Weapons: Ozempic, Wegovy, and Shipping</h2>
Denmark may be small, but it holds the keys to critical industries that Americans depend on, especially pharmaceuticals and global shipping.
<h3 class="wp-block-heading">1. Novo Nordisk Could Cut Off Ozempic and Wegovy</h3>
Denmark is home to Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), the company behind <a href="https://www.benzinga.com/25/01/43055832/novo-nordisks-higher-dose-of-wegovy-shows-weight-loss-of-around-21-phase-3-data-shows">Ozempic and Wegovy</a>, two of the most in-demand drugs in the U.S. for weight loss and diabetes treatment. With demand for those drugs skyrocketing, Novo Nordisk has been expanding production in the U.S. But the active ingredient, semaglutide, is made in Denmark. If Denmark ordered Novo Nordisk to stop supplying the U.S., the supply of the drugs in the U.S. would disappear overnight.
Millions of Americans rely on Ozempic and Wegovy, and demand is so high that the U.S. has already faced shortages. On the other hand, Novo Nordisk would likely have no issues finding plenty of customers in other markets.&nbsp;
Trending: According to Juniper Research, the total value of B2B cross-border payments stored on the blockchain is projected to exceed $4.4 trillion — <a href="https://www.benzinga.com/money/web3-enabler-future-of-enterprise-transactions">Join the first company to bring blockchain payments to Salesforce early with just $100.</a>
<h3 class="wp-block-heading">2. Maersk Could Halt U.S. Shipping</h3>
Denmark is also home to Maersk, the world's second-largest container shipping company, which transports 14.3% of the global container fleet. If Maersk were to stop shipping goods to and from the U.S., it would cause immediate chaos in supply chains.
Major U.S. ports like Los Angeles, Houston, and New York rely on Maersk for everything from electronics to clothing. Since global shipping is already near full capacity, there wouldn't be enough ships available to pick up the slack. This would drive up shipping costs and lead to shortages of everyday products in the U.S.
Beyond that, Denmark is also a major supplier of <a href="https://www.benzinga.com/news/24/04/38045479/lego-billionaires-wealth-surges-as-investment-portfolio-turns-profitable">Lego toys</a>, hearing aids, insulin, medical instruments, and pork. Tariffs or trade restrictions could send prices skyrocketing on all of these products, hurting American consumers more than Denmark.
Trending: Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a>
<h2 class="wp-block-heading">Trump's Tariff Pause on Mexico and Canada Adds More Uncertainty</h2>
Just days ago, Trump announced a <a href="https://www.benzinga.com/government/regulations/25/02/43440692/us-mexico-agrees-on-one-month-tariffs-pause-stocks-rebound-peso-rallies">one-month pause</a> on tariffs against Mexico and Canada after last-minute talks. Mexico agreed to deploy 10,000 troops to its border to curb fentanyl trafficking and illegal migration, while Canada committed to tightening border security and implementing a $1.3 billion border plan.
But this pause doesn't mean tariffs are off the table. Trump is still threatening more trade wars, and Denmark and the whole EU are the next target. If Trump imposes tariffs on European exports, it would raise prices on EU goods coming into the U.S., making products like pharmaceuticals, medical devices, and food products significantly more expensive for American consumers.
See Also: Built on the trusted network of Fortune 500 companies, <a href="https://www.benzinga.com/money/web3-enabler-the-most-boring-blockchain-company-partners-with-salesforce">this blockchain company partners with Salesforce to uproot lengthy and expensive B2B transactions, and you can invest with just $100.</a>
<h2 class="wp-block-heading">Denmark&#8217;s Economic Might is No Joke</h2>
Denmark may be a small country, but it has massive leverage over the U.S. economy. If Trump pushes too hard on Greenland, Denmark could strike back in ways that everyday Americans would feel immediately. From sky-high drug prices to shipping disruptions, Trump's threats of tariffs could backfire in a big way.
For now, <a href="https://www.benzinga.com/24/12/42679581/trump-effect-denmark-boosts-greenlands-defense-budget-amid-president-elects-renewed-acquisition-interest">Denmark is standing firm</a>, and <a href="https://www.benzinga.com/startups/25/01/43083783/we-dont-want-to-be-americans-greenlanders-speak-out-on-trumps-plan">Greenland isn't for sale</a>. The question is: Will Trump push Denmark too far and spark an economic war he wasn't expecting?
Read Next:
<ul>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
<li>If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?</li>
</ul>
Image from ShutterStock

Denmark Could Ban Or Push Ozempic, Wegovy And Shipping Prices Through The Roof If Trump Escalates Over Greenland

Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) announced that its weight-loss drug Wegovy has reached 1.2 million U.S. patients. Of these, 55 million individuals are covered by insurance, and over 80% pay less than $25 per prescription, according to statements made during the company&#8217;s <a href="https://www.benzinga.com/25/02/43491991/novo-nordisk-records-more-than-double-wegovy-sales-in-q4-seeks-regulatory-approval-for-hybrid-weight-loss-drug-in-2026" target="_blank" rel="noopener">fourth-quarter 2024 earnings call</a>.
What Happened: The Danish pharmaceutical giant faces potential challenges as semaglutide-containing products, including Wegovy, Ozempic, and Rybelsus, have been selected for the second round of Centers for Medicare and Medicaid Services (CMS) price negotiations. 
The negotiations are set to conclude in early November, with maximum fair prices to be published by month-end and implementation scheduled for Jan.1, 2027.
&#8220;We oppose government price setting like we have from the beginning,&#8221; stated David Moore, Executive Vice President of U.S. Operations and Global Business Development at Novo Nordisk. 
The pricing debate has drawn attention from diverse quarters, including Tesla Inc. CEO Elon Musk and Sen.&nbsp;Bernie Sanders, (I-VT), who have both criticized the <a href="https://www.benzinga.com/personal-finance/24/09/41082125/stop-ripping-us-off-incredibly-elon-musk-and-bernie-sanders-seem-to-agree-on-this-one-thing-i-re">drug&#8217;s high U.S. costs</a>. 
Sanders highlighted that Wegovy&#8217;s monthly prescription costs $1,349 in the U.S., compared to significantly lower prices in other countries: $186 in Denmark, $140 in Germany, and $92 in the U.K.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43518087/official-trump-coin-jumps-427-but-still-75-below-januarys-all-time-high">TRUMP Meme Coin Jumps 4.27%, Outpaces Bitcoin, Ethereum, And Dogecoin, But It&#8217;s Still Nowhere Near January Highs</a>
Why It Matters: The situation has become more complex with the involvement of Musk&#8217;s Department of Government Efficiency (DOGE), which has gained access to CMS systems. The move is part of a broader initiative to identify potential fraud and waste in government healthcare spending, though CMS maintains that two senior agency veterans are overseeing the collaboration to ensure appropriate system access.
Despite these challenges, Novo Nordisk remains focused on market expansion. &#8220;Building a sustainable obesity market for the long term is through market access and having patients have a reasonable co-pay,&#8221; Moore said. 
Looking ahead, Novo Nordisk <a href="https://www.benzinga.com/25/02/43491991/novo-nordisk-records-more-than-double-wegovy-sales-in-q4-seeks-regulatory-approval-for-hybrid-weight-loss-drug-in-2026">projects sales growth</a> between 16% and 24% in constant exchange rates for 2025, though this represents a decrease from the 26% growth achieved in 2024. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43519568/ubers-strong-q4-offset-by-11-billion-forex-headwind-currency-devaluation-thanks-to-tariff-wars-drives-weak-q1-outlook">Uber&#8217;s Strong Q4 Offset By $1.1 Billion Forex Headwind, Currency Devaluation: Ongoing Tariff Wars Drive Weak Q1 Outlook</a></li>
</ul>
Image Via Shutterstock 
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Equities

Novo Nordisk Opposes 'Government Price Setting' As Elon Musk's DOGE Gains Access To CMS Amid Bernie Sanders' Criticism

Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) will announce its fourth-quarter 2024 financial results and 2025 financial guidance on&nbsp;February 6. As per data from Benzinga Pro, the Wall Street estimates sales of $13.7 billion, with <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">adjusted EPS of $4.94</a>.
In January, just before the&nbsp;JP Morgan healthcare conference,&nbsp;Eli Lilly announced that it expects 2024 full-year worldwide revenue to be approximately&nbsp;$45.0 billion, representing a 32% growth compared to the previous year versus the&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/43013223/eli-lilly-adjusts-outlook-ceo-david-ricks-explains-revenue-shortfall" rel="noreferrer noopener">consensus of $45.50 billion</a>.
The company&#8217;s expected 2024 revenue is&nbsp;$400 million, or about 3%, below the guidance range issued during the&nbsp;third-quarter earnings. The guidance includes approximately&nbsp;$3.5 billion&nbsp;for Mounjaro and $1.9 billion&nbsp;for Zepbound.
Also Read: <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/01/43403416/is-big-pharma-about-to-win-goldman-sachs-weighs-in-on-340b-and-medicaid-shifts" rel="noreferrer noopener">Is Big Pharma About To Win? Goldman Sachs Weighs In On 340B And Medicaid Shifts</a>
Analysts are tracking Eli Lilly&#8217;s expected increase in sales and profit in the first full quarter, during which its weight-loss drugs ceased to be in shortage.
In October 2024, the FDA determined that&nbsp;Eli Lilly&#8217;s tirzepatide injection shortage <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/42783449/eli-lilly-joins-fda-lawsuit-over-compounded-obesity-drugs-seeks-swift-end-and-to-protect-its-interests" rel="noreferrer noopener">had been resolved</a>.
The U.S. pharma giant reported third-quarter revenue of $11.44 billion, up 20% year over year, but it missed the <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41622207/eli-lilly-q3-earnings-mounjaro-sales-more-than-double-takes-2-98-billion-hit-to-profit-cuts-annua" rel="noreferrer noopener">consensus of $12.10 billion</a>. Mounjaro sales more than doubled to $3.11 billion from $1.41 billion a year ago.
Sales of Verzenio (a breast cancer drug)&nbsp;increased 32% to&nbsp;$1.37 billion, and sales of diabetes drug Jardiance&nbsp;fell 2% to&nbsp;$686.4 million.
Zepbound sales reached $1.26 billion. Trulicity sales fell 22% to&nbsp;$1.30 billion.
Rival Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) stock is trading higher. On Wednesday, the company reported sales of roughly $12.25 billion (85.68 billion Danish kroner) for the fourth quarter of 2024, beating the consensus of $11.34 billion (<a target="_blank" href="https://www.benzinga.com/25/02/43491991/novo-nordisk-records-more-than-double-wegovy-sales-in-q4-seeks-regulatory-approval-for-hybrid-weight-loss-drug-in" rel="noreferrer noopener">79.73 billion Danish Kroner</a>).
GLP-1 diabetes sales increased by 12%, and Obesity care sales increased by 91%.
Ozempic sales increased 12% to 33.85 billion Danish kroner, and Wegovy sales more than doubled to 19.87 billion Danish kroner.
According to Reuters, investors and analysts expect Eli Lilly to outline its strategy for promoting Zepbound this year as it aims to compete with Wegovy, a more established drug.
Zepbound holds a little over 50% of the market, according to IQVIA data cited by an analyst. Eli Lilly began advertising the drug in November.
Price Action: LLY stock is up 2.19% at $843.59 at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43496469/aircraft-manufacturer-embraer-bags-7b-order-stocks-surge" target="_blank" rel="noreferrer noopener">Embraer Lands Record $7 Billion Flexjet Order, Stock Jumps</a></li>
</ul>
Image by Mohammed_Al_Ali via Shutterstock

Earnings

Guidance

Analyst Ratings

What To Expect When Eli Lilly Reports Q4 Earnings On Thursday?

WIIM

Novo Nordisk shares are trading higher after the company reported Q4 financial results and beat its EPS and revenue estimates.

On Wednesday, Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) reported sales of roughly $12.25 billion (85.68 billion Danish kroner) for the fourth quarter of 2024, beating the consensus of $11.34 billion (79.73 billion Danish Kroner).
Sales increased by 30% in Danish kroner and at CER compared to 2023.
GLP-1 diabetes sales increased by 12% at CER to 42.17 billion Danish kroner, and Obesity care sales increased by 91% at <a target="_blank" href="https://www.benzinga.com/25/02/43459558/novo-nordisk-faces-investor-concerns-over-hybrid-cagrisema-trial-results-for-weight-loss" rel="noreferrer noopener">CER to 21.41 billion Danish kroner</a>.
Ozempic <a target="_blank" href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=915255" rel="noreferrer noopener">sales</a> increased 12% to 33.85 billion Danish kroner, and Wegovy sales more than doubled <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43475491/novo-nordisk-stock-q4-earnings-analysts-68-upside" rel="noreferrer noopener">to 19.87 billion Danish kroner</a>.
Insulin sales increased 36% to 15.9 billion Danish kroner, and Rare disease sales increased 25% at CER to 5.71 billion Danish kroner.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/01/43321236/rfk-jr-and-big-pharma-stocks-to-watch-as-health-secretary-hopeful-answers-pointed-questions-on-drugs-insurance-trump-exec-orders" rel="noreferrer noopener">RFK Jr. And Big Pharma: Health Secretary Hopeful Answers Pointed Questions On Drugs, Insurance, Trump Exec Orders</a>
The Danish pharmaceutical giant&#8217;s net profit increased by 29% to 28.23 billion kroner, with EPS of 6.34 Danish kroner, up 29%, beating the consensus of 5.82 Danish kroner. In USD terms, EPS of $0.91 beat $0.83 consensus.
In its earnings release, Novo Nordisk outlined its plans to conduct a new phase 3 trial in 2025 to further explore <a target="_blank" href="https://www.benzinga.com/24/12/42613036/novo-nordisks-hybrid-weight-loss-drug-falls-short-on-expectations-stock-plunges" rel="noreferrer noopener">CagriSema&#8217;s weight-loss potential</a>.
The results from the second pivotal phase 3 trial, REDEFINE 2, of CagriSema in adults with type 2 diabetes and either obesity or overweight are expected during the first quarter of 2025
To secure <a target="_blank" href="https://ml-eu.globenewswire.com/Resource/Download/365675dd-10f3-4293-9aec-ede9f63375c6" rel="noreferrer noopener">supply</a> chain readiness, the company now expects to file for the first regulatory approval of CagriSema during the first quarter of 2026.
Guidance: Novo Nordisk expects sales growth of between 16% and 24% in constant exchange rates this year, lower than the 26% achieved in 2024.
&#8220;In 2025, we will continue our focus on commercial execution, on the progression of our early and late-stage R&amp;D pipeline and on the expansion of our production capacity,&#8221; Chief Executive Lars Fruergaard Jorgensen said.
The company expects 2025 operating profit growth of 19% to 27% in constant exchange rates.
Novo Nordisk adds that the outlook reflects expected continued periodic supply constraints and related drug shortage notifications across several products and geographies. Novo Nordisk is investing in internal and external capacity to increase supply in the short and long term.
Price Action: At last check on Wednesday, NVO stock was up 3.09% at $85.17 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43475015/spotifys-strong-subscriber-growth-and-rising-margins-keep-analysts-bullish" target="_blank" rel="noreferrer noopener">Spotify Is Still One Of Top 4 Best Ideas For 2025: Analyst</a></li>
</ul>
Photo via Shutterstock

Movers

Novo Nordisk Q4 Earnings: Wegovy Sales More Than Double, Seeks Regulatory Approval For Hybrid Weight Loss Drug In 2026

ALGN

AMSC

AOSL

APPS

ARAY

ARCC

ARES

ASGN

ASYS

AZTA

BARK

BLBD

BSBR

CENT

CENTA

CMRE

CNMD

CNXN

COHR

CPAY

CPRI

CRTO

CSGS

CTSH

CTVA

DGII

DLHC

ENSG

EQNR

EZPW

FORM

GEOS

HOLX

ITUB

KMPR

LFVN

LSAK

LUCK

LVWR

MSTR

MTRX

MUSA

NOTV

NTGR

NVST

NWSA

ODFL

ORLY

PAHC

PFGC

Earnings Scheduled For February 5, 2025

<ul>
<li>For the 2025 outlook, sales growth is expected to be 16-24% at CER, and operating profit growth is expected to be 19-27% at CER. Sales and operating profit growth reported in Danish kroner is expected to be 3 and 5 percentage points higher than at CER, respectively.</li>
</ul>

Novo Nordisk Forecasts 2025 Sales Growth Of 16%-24% And Operating Profit Growth At CER Of 19-27%

Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) reported quarterly earnings of DKK6.34 per share which beat the analyst consensus estimate of DKK 5.82 by 8.93 percent. This is a 29.12 percent increase over earnings of DKK 4.91 per share from the same period last year. The company reported quarterly sales of DKK 85.683 billion which beat the analyst consensus estimate of DKK 79.730 billion by 7.47 percent. This is a 30.09 percent increase over sales of DKK 65.863 billion the same period last year.

Earnings Beats

Novo Nordisk Q4 2024 GAAP EPS DKK 6.34 Beats DKK 5.82 Estimate, Sales DKK 85.683B Beat DKK 79.730B Estimate

Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) has outperformed the market over the past 5 years by 8.62% on an annualized basis producing an average annual return of 21.07%. Currently, Novo Nordisk has a market capitalization of $367.51 billion. 
Buying $100 In NVO: If an investor had bought $100 of NVO stock 5 years ago, it would be worth $261.75 today based on a price of $82.78 for NVO at the time of writing.
<h3>Novo Nordisk's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738701009_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Novo Nordisk 5 Years Ago Would Be Worth This Much Today

Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) will report its fourth-quarter earnings on Wednesday. Wall Street expects 86 cents in EPS and $11.40 billion in revenues as the company reports<a href="https://www.benzinga.com/calendars/earnings?tickers=NVO" target="_blank" rel="noreferrer noopener"> before market hours</a>.
The stock is down 29.55% over the past year, 4.81% YTD.
Let&#8217;s look at what the charts indicate for Novo Nordisk stock and how the stock currently maps against Wall Street estimates.
Read Also: <a href="https://www.benzinga.com/25/02/43459558/novo-nordisk-faces-investor-concerns-over-hybrid-cagrisema-trial-results-for-weight-loss">Novo Nordisk Faces Investor Concerns Over Hybrid CagriSema Trial Results For Weight Loss</a>
<h1 class="wp-block-heading">Novo Nordisk Stock Strongly Bearish Ahead of Q4 Earnings</h1>
Novo Nordisk stock, at $83.18, is currently under strong bearish pressure, trading below its five-day, 20-day and 50-day exponential moving averages. This suggests a persistent downtrend with limited short-term momentum.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020425&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="626" height="490" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04125717/Screenshot-2025-02-04-at-11.09.08-PM.png" alt="" class="wp-image-765368" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04125717/Screenshot-2025-02-04-at-11.09.08-PM.png 626w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04125717/Screenshot-2025-02-04-at-11.09.08-PM-300x235.png 300w" sizes="(max-width: 626px) 100vw, 626px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020425&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
The eight-day simple moving average (SMA) of $85.04 and 20-day SMA of $83.69 both signal bearish conditions, indicating that Novo Nordisk stock has struggled to regain upward traction.
Additionally, the stock&#8217;s position well below its 50-day SMA of $94.26 and 200-day SMA of $120.12 reinforces the broader downtrend.
Momentum indicators further support the bearish outlook. The Moving Average Convergence Divergence (MACD) indicator is at a negative 2.60, signaling continued weakness, while the Relative Strength Index (RSI) sits at 41.89, hovering just above oversold territory. 
Investors should monitor whether Novo Nordisk stock finds support at current levels or risks further downside. A sustained move above the 20-day SMA could hint at a potential trend reversal, while continued weakness may lead to further selling pressure.
<h1 class="wp-block-heading">Novo Nordisk Analysts See 68% Upside</h1>
Ratings &amp; Consensus Estimates:<a href="https://www.benzinga.com/quote/NVO/analyst-ratings" target="_blank" rel="noreferrer noopener"> The consensus analyst rating</a> on Novo Nordisk stock stands at a Buy currently with a price target of $116.57. Recent analyst ratings from BMO Capital and Cantor Fitzgerald suggest a 68.47% upside for NVO stock.
NVO Stock Price Action: Novo Nordisk stock was trading down 3.55% at $82.97 at the time of publication Tuesday.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/health-care/25/01/43321236/rfk-jr-and-big-pharma-stocks-to-watch-as-health-secretary-hopeful-answers-pointed-questions-on-drugs-insurance-trump-exec-orders">RFK Jr. And Big Pharma: Health Secretary Hopeful Answers Pointed Questions On Drugs, Insurance, Trump Exec Orders</a></li>
</ul>
Photo: Shutterstock

Novo Nordisk Stock Slides Before Q4 Earnings: Analysts Still See 68% Upside

In December, Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) released headline results from the REDEFINE 1 Phase 3 trial in the&nbsp;<a target="_blank" href="https://www.benzinga.com/24/12/42613036/novo-nordisks-hybrid-weight-loss-drug-falls-short-on-expectations-stock-plunges" rel="noreferrer noopener">global REDEFINE program</a>.
When evaluating the effects of treatment if all people adhered to treatment, people treated with CagriSema achieved a weight loss of 22.7% after 68 weeks compared to a reduction of 11.8% with cagrilintide 2.4 mg, 16.1% with semaglutide 2.4 mg and 2.3% with placebo alone.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/43055832/novo-nordisks-higher-dose-of-wegovy-shows-weight-loss-of-around-21-phase-3-data-shows" rel="noreferrer noopener">Novo Nordisk's Higher Dose Of Wegovy Shows Roughly 21% Weight Loss</a>
In interviews with Reuters, some investors, analysts, and trial participants have raised concerns over CagriSema's side effects, dosing protocol, and effectiveness compared to Eli Lilly And Co's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">Zepbound (Mounjaro)</a>.
Five patients from the REDEFINE-1 and REDEFINE-4 trials interviewed by Reuters said CagriSema helped them lose weight rapidly, but side effects, such as nausea, constipation, and fatigue, were significant.
The weaker-than-expected trial data has raised doubts about Novo Nordisk's ability to compete with Eli Lilly's weight-loss drug.
In November, Novo Nordisk said its hybrid drug, CagriSema, aims to reduce weight by 25% without&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41706292/as-race-to-best-miracle-obesity-drug-heats-up-ozempic-maker-novo-nordisk-tests-new-hybrid-drug-th" rel="noreferrer noopener">added side effects</a>.
A key issue emerging from the trial is that only 57.3% of patients reached the highest dose of CagriSema. Novo has not clarified whether this was due to intolerable side effects or effective weight loss at lower doses.
Investors and analysts were also surprised by the study's flexible dosing protocol, which allowed participants to adjust their dosage instead of following a strict schedule.
Some believe this contributed to the low uptake of the highest dose and may have affected overall trial results.
Novo Nordisk will release its fourth quarter 2024 earnings on Wednesday. Analysts expect sales of DKK 79.73 billion and EPS of DKK 5.86 as per data from <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">Benzinga Pro</a>.
Reuters, citing a Barclays analyst, noted that the lack of clarity has fueled negative sentiment, with concerns that CagriSema may be less effective than Eli Lilly's Zepbound, have worse tolerability, and be more difficult to manufacture.
Last week, Novo Nordisk&nbsp;released topline results from a phase 1b/2a trial with amycretin intended for once-weekly subcutaneous administration.
When evaluating the effects of treatment if all people adhered to treatment&nbsp;from a mean baseline body weight of 92.7 kg, people treated with amycretin achieved an estimated body weight loss of 9.7% on 1.25mg (20 weeks), 16.2% on 5mg (28 weeks) and 22.0% on <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/43187095/novo-nordisks-weekly-amycretin-delivers-up-to-22-weight-loss-in-study-stock-soars" rel="noreferrer noopener">20mg (36 weeks)</a>.
Price Action: At last check on Tuesday, NVO stock was down 0.94% to $81.87 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/02/43444040/dan-loebs-third-point-trims-amazon-microsoft-meta-as-tech-stocks-climb" target="_blank" rel="noreferrer noopener">Dan Loeb's Third Point Trims Amazon, Microsoft, Meta As Tech Stocks Climb</a></li>
</ul>
Photo via Shutterstock

Media

Novo Nordisk Faces Investor Concerns Over Hybrid CagriSema Trial Results For Weight Loss

Whales with a lot of money to spend have taken a noticeably bullish stance on Novo Nordisk.
Looking at options history for Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) we detected 8 trades.
If we consider the specifics of each trade, it is accurate to state that 50% of the investors opened trades with bullish expectations and 37% with bearish.
From the overall spotted trades, 5 are puts, for a total amount of $271,120 and 3, calls, for a total amount of $100,924.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $65.0 to $110.0 for Novo Nordisk over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
In today's trading context, the average open interest for options of Novo Nordisk stands at 1425.0, with a total volume reaching 5,628.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Novo Nordisk, situated within the strike price corridor from $65.0 to $110.0, throughout the last 30 days.
<h3>Novo Nordisk Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738597545_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$3.7</td>
<td>$3.6</td>
<td>$3.65</td>
<td>$83.00</td>
<td>$137.2K</td>
<td>374</td>
<td>377</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$0.17</td>
<td>$0.06</td>
<td>$0.1</td>
<td>$65.00</td>
<td>$45.0K</td>
<td>5.5K</td>
<td>5.0K</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/14/25</td>
<td>$3.8</td>
<td>$3.75</td>
<td>$3.8</td>
<td>$84.00</td>
<td>$38.0K</td>
<td>125</td>
<td>103</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/07/25</td>
<td>$2.36</td>
<td>$2.18</td>
<td>$2.37</td>
<td>$84.00</td>
<td>$35.5K</td>
<td>643</td>
<td>9</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/07/25</td>
<td>$6.65</td>
<td>$6.55</td>
<td>$6.6</td>
<td>$77.00</td>
<td>$34.3K</td>
<td>10</td>
<td>52</td>
</tr>
</tbody>
</table>

<h3>About Novo Nordisk</h3>
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
<h3>Where Is Novo Nordisk Standing Right Now?</h3>
<ul>
<li>With a trading volume of 1,627,289, the price of NVO is down by -1.71%, reaching $83.01.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 2 days from now.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Novo Nordisk with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Spotlight on Novo Nordisk: Analyzing the Surge in Options Activity

Novo Nordisk Says New Phase III Trial Of Obesity Drug Candidate Cagrisema Launching On Feb. 10 Will Study Long-Term Efficacy Of Cagrisema, Part Of Redefine Series; Says It Has Not Yet Posted Details About New Cagrisema Trial To Test Weight Loss In Obesity Patients Planned After Late-Stage Trial Data In December

https://clinicaltrials.gov/study/NCT06780449?spons=Novo%20Nordisk%20A%2FS&amp;titles=cagrisema&amp;rank=6`

Novo Nordisk To Begin New Phase III Trial Of Obesity Drug Candidate Cagrisema

Robert F. Kennedy Jr., President Donald Trump's pick for health secretary, addressed a wide range of medical-related topics on Wednesday during a confirmation hearing with <a href="https://www.benzinga.com/25/01/43306674/trumps-hhs-pick-robert-kennedy-jr-begins-senate-confirmation-hearings">the Senate Finance Committee.</a>
While Kennedy&#8217;s tone in each back-and-forth varied, depending on the senator, it was evident that Kennedy&#8217;s role in the new administration would have a tremendous impact on both pharma and insurance stocks.
<h3 class="wp-block-heading">Drug Price Negotiation</h3>
During one exchange about the high cost of drugs with Senator Catherine Cortez Masto (D-NV), Kennedy said: "Senator, my understanding is that the White House issued an executive order, I believe today, supporting the drug negotiations under the I.R.A. President Trump was very aggressive during his first term about negotiating drug prices."
In reality, Trump has not signed an executive order on the topic since he was sworn into office. A Wednesday news <a href="https://www.cms.gov/newsroom/press-releases/cms-statement-lowering-cost-prescription-drugs" target="_blank" rel="noreferrer noopener">release</a> from the Centers for Medicare and Medicaid Services said that lowering the cost of prescription drugs for Americans &#8220;a top priority&#8221; for the Trump administration and that he would work to improve the transparency of the negotiation process.
Perhaps Kennedy was recalling Trump&#8217;s first term. In 2020, then-45th President Trump <a href="https://www.benzinga.com/general/biotech/20/09/17482940/trump-signs-executive-order-to-lower-us-drug-prices-after-negotiations-with-drugmakers-fail">signed an executive order</a> on U.S. Medicare drug prices intending to reduce costs. Industry leaders, including Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) CEO Albert Bourla, criticized the move. Pfizer was seeking regulatory approval to expand its late-stage vaccine trial at the time.
If Trump signs such an order, it would be a rare show of support from his camp for a Biden-era initiative. In addition to Pfizer, it would also impact major companies like Bristol Myers Squibb, Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), Merck &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), AstraZeneca (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), Novartis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) and AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>).
Last month, the Biden administration <a href="https://www.benzinga.com/25/01/43062779/popular-ozempic-wegovy-selected-for-next-round-of-medicare-drug-price-negotiations">identified the next 15 drugs</a> as subject to negotiation. The list included Ozempic and Wegovy — two expensive drugs for diabetes and obesity owned by Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>).
See Also: <a href="https://www.benzinga.com/25/01/43306674/trumps-hhs-pick-robert-kennedy-jr-begins-senate-confirmation-hearings">RFK Jr. Is A &#8216;Predator&#8217; Unfit For Office, Caroline Kennedy Says </a>
<h3 class="wp-block-heading">Insurance Providers</h3>
According to the <a href="https://www.nytimes.com/live/2025/01/29/us/rfk-jr-health-senate-hearing">New York Times</a>, Kennedy wasn&#8217;t exactly familiar with Medicare and Medicaid, but expressed support for Medicare Advantage, where private insurers provide coverage for elderly Americans.
Kennedy also called out what he considered to be &#8220;rapacious behavior by insurance companies." He even suggested he would support some of the efforts undertaken during the Biden administration to crack down on abusive tactics like denying care and overcharging the government.
Traders would be wise to keep an eye on how insurance stocks — especially those tied to Medicaid and Medicare providers — react if Kennedy is sworn in. The major players in this space include: 
UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), the largest Medicare Advantage insurer in the U.S.; Centene Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>); Elevance Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>), one of the largest Medicaid managed care organizations; Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>); CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>); Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>); and Cigna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>).
What&#8217;s Next: Kennedy seeks to be Secretary of Health and Human Services — a position that would put him in charge of the health of the American people.
The title also puts him in charge of the Food and Drug Administration, the National Institutes of Health and the Centers for Disease Control and Prevention.
He will appear before the Senate Committee on Health, Education Labor and Pensions on Thursday.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/news/25/01/43216758/well-go-as-far-as-im-allowed-trumps-plan-with-immigrants-starts-with-1-million-deportations" target="_blank" rel="noreferrer noopener">‘We'll Go As Far As I'm Allowed': Trump's Plan With Immigrants Starts With 1 Million Deportations</a></li>
</ul>
Image: Shutterstock

Insurance

ABBV

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

RFK Jr. And Big Pharma: Health Secretary Hopeful Answers Pointed Questions On Drugs, Insurance, Trump Exec Orders

The Food and Drug Administration on Tuesday approved Ozempic, the weight loss drug made by Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), for the treatment of chronic kidney disease in patients who also <a href="https://www.benzinga.com/25/01/42875977/novo-nordisk-seeks-to-strengthen-its-obesity-pipeline-with-back-to-back-two-biobuck-deals">have type 2 diabetes. </a>
The Details: According to the Centers for Disease Control and Prevention, more than 35.5 million Americans have chronic kidney disease, often as a complication of type 2 diabetes. The new FDA approval allows for further expansion of Ozempic's use and potential coverage by health insurance plans.&nbsp;
Read Next:<a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/43254018/sofi-stock-falls-on-soft-guidance-despite-strong-quarter-with-record-member-growth-loan-originations-analyst"> SoFi Stock Falls On Soft Guidance Despite &#8216;Strong Quarter&#8217; With Record Member Growth, Loan Originations: Analyst&nbsp;</a>
The FDA approval "allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of adults and could have serious consequences if left untreated," Anna Windle, a senior vice president at Novo Nordisk, said in a statement Tuesday, per a Bloomberg <a href="https://www.bloomberg.com/news/articles/2025-01-28/novo-s-ozempic-notches-approval-for-kidney-disease-widening-use?sref=TBDibEcD">report</a>.&nbsp;
Ozempic and other diabetes drugs known as GLP-1s have become popular and also well-known for their high cost.&nbsp;
Earlier in January, Novo Nordisk's diabetes and weight loss drugs, Ozempic, Rybelsus, and Wegovy were all added to the U.S. Department of Health and Human Services list of drugs covered under Medicare Part D that<a href="https://www.benzinga.com/25/01/43062779/popular-ozempic-wegovy-selected-for-next-round-of-medicare-drug-price-negotiations"> have been selected</a> for mandated price negotiations in order to reduce <a href="https://www.benzinga.com/general/biotech/24/08/40534249/novo-nordisks-ozempic-might-be-among-2027-medicare-price-negotiation-targets">prescription drug costs</a>.
The negotiations will take place in 2025, with the new prices slated to take effect in 2027.
NVO Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Novo Nordisk shares ended Tuesday's session down 2.65% at $85.19.&nbsp;
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/25/01/43287988/microsoft-q2-preview">Microsoft Q2 Earnings Preview: Street &#8216;Too Optimistic&#8217; On Near-Term AI Returns?&nbsp;</a></li>
</ul>
Photo: Shutterstock

Ozempic Receives FDA Approval To Treat Kidney Disease

<ul>
<li>Ozempic&#xAE; is now indicated to reduce the risk of kidney disease worsening, kidney failure, and death from cardiovascular disease in adults with type 2 diabetes and chronic kidney disease</li>
<li>The approval is based on the results of the pivotal FLOW phase 3b kidney outcomes trial and addresses a critical need for adults with type 2 diabetes living with this common comorbidity of chronic kidney disease&nbsp;</li>
</ul>
PLAINSBORO, N.J., Jan. 28, 2025 /PRNewswire/ -- Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved Ozempic&#xAE;&nbsp;to reduce the risk of kidney disease worsening, kidney failure (end-stage kidney disease), and death due to cardiovascular disease in adults with type 2 diabetes and chronic kidney disease (CKD).1&nbsp;This approval, along with its existing indications for adults with type 2 diabetes to improve glycemic control and to reduce the risk of major cardiovascular events in adults also with known heart disease, establishes Ozempic&#xAE;&nbsp;(semaglutide) injection 0.5 mg, 1 mg, or 2 mg as the most broadly indicated glucagon-like peptide-1 receptor agonist (GLP-1 RA) in its class.

FDA Approves Ozempic As The Only GLP-1 RA To Reduce The Risk Of Worsening Kidney Disease And Cardiovascular Death In Adults With Type 2 Diabetes And Chronic Kidney Disease

The rise of appetite-suppressing drugs like Ozempic is changing the way Americans eat, but there's a twist: <a href="https://www.benzinga.com/cannabis">cannabis</a> legalization is pulling consumer behavior in the opposite direction. Bloomberg's <a href="https://www.bloomberg.com/prognosis?sref=TBDibEcD">Prognosis newsletter</a> recently dug into this fascinating interplay, highlighting how these two trends are reshaping the food industry and public health.
<h3 class="wp-block-heading">The Ozempic Effect: Appetite On Pause</h3>
Ozempic, Wegovy and other GLP-1 agonists have become household names for their remarkable ability to help people shed pounds. These drugs don't just curb appetite, they're also influencing what people buy. According to a <a href="https://www.bloomberg.com/news/articles/2024-02-16/ozempic-users-cut-grocery-spending-by-up-to-9-survey-finds">Morgan Stanley report</a>, households using GLP-1 drugs have cut their spending on snacks, pastries and ice cream by 6% to 9%. Meanwhile, healthier options like yogurt and vegetable snacks are seeing a boost, as companies like Danone (OTC:<a class="ticker" href="https://www.benzinga.com/stock/DANOY#OTC">DANOY</a>) and Nestlé adjust their product lines to meet demand.
Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), maker of Ozempic, has even <a href="https://finance.yahoo.com/news/novo-nordisk-ceo-says-fielding-114820887.html">received calls</a> from food industry leaders worried about the drug's impact. And they have reason to be concerned: Walmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) has <a href="https://www.bloomberg.com/news/articles/2023-10-04/walmart-says-ozempic-weight-loss-drugs-causing-slight-pullback-by-shoppers">reported</a> that households with GLP-1 users are buying less food overall. As the popularity of these drugs grows, with the market <a href="https://www.jpmorgan.com/insights/global-research/current-events/obesity-drugs">projected</a> to hit $100 billion by 2030, the ripple effects are only just beginning.
<h3 class="wp-block-heading">Cannabis Legalization: The Munchies Are Big Business</h3>
On the flip side, marijuana legalization is sparking a very different trend. With recreational cannabis now legal in 24 states, the infamous &#8220;<a href="https://elplanteo.com/munchies/">munchies</a>&#8221; are giving a major boost to junk food sales. Researchers from the <a href="https://www.nber.org/papers/w33176">National Bureau of Economic Research</a> found that grocery spending on snacks, cookies and candy jumped nearly 9% in states that legalized recreational marijuana.
<h3 class="wp-block-heading">A Collision Of Cultural Forces</h3>
These two trends &#8211; Ozempic's appetite-suppressing revolution and cannabis' munchies-driven consumption &#8211; paint a complex picture of American eating habits. On one side, GLP-1 drugs are helping people slim down and rethink their diets. On the other, marijuana legalization is encouraging indulgence, particularly in the form of high-calorie comfort foods.
Companies are scrambling to adapt. Nestlé and Conagra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAG#NYSE">CAG</a>), for instance, are launching new products designed to appeal to both GLP-1 users and cannabis consumers. Think high-protein, portion-controlled frozen meals that cater to health-conscious shoppers, alongside indulgent snacks that satisfy the munchies. It's a balancing act and a testament to the food industry's ability to pivot with the times.
<h3 class="wp-block-heading">The Bigger Picture: Health And Economics</h3>
Cannabis legalization has brought tangible economic benefits, including increased GDP, job creation and tax revenue for states where it's legal. For example, Colorado and California have reported billions in tax revenue since legalization. Moreover, cannabis policies have helped reduce arrests and shifted law enforcement resources toward other priorities, fostering a growing legal industry that has supported local economies.
At the same time, public health challenges remain. Research indicates mixed outcomes. While substance use and dependency have increased slightly in some states, other studies highlight a decrease in opioid-related deaths and alcohol consumption, suggesting cannabis can serve as a harm-reduction tool.
Meanwhile, GLP-1 drugs present their own set of challenges. While they offer a promising tool in combating obesity, their rapid adoption is forcing industries reliant on indulgent eating, from fast food to snacks, to rethink their strategies. Questions about the long-term effects of these drugs and their impact on consumer behavior remain unanswered.
<h3 class="wp-block-heading">What's Next?</h3>
The intersection of Ozempic's appetite suppression and cannabis's munchies effect highlights the complexity of consumer trends in the U.S. Will GLP-1 drugs lead to healthier lifestyles, or will the munchies win out? For now, it's clear that both trends are reshaping industries and pushing companies to innovate like never before.
Cover image made with Canva

Cannabis

DANOY

How Ozempic And Legal Weed Are Changing What America Eats

Novo Nordisk ( ($NVO) ) has released its Q4 earnings. Here is a breakdown of the information Novo Nordisk presented to its investors. Novo Nordisk ...

Novo Nordisk Reports Strong 2024 Earnings Growth

In a report released today, Jo Walton from UBS maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price target of DKK750.00. ...

Novo Nordisk (0QIU) Gets a Buy from UBS

An announcement from Novo Nordisk ( ($NVO) ) is now available. On February 6, 2025, Novo Nordisk announced that its board members, executives, and ...

Novo Nordisk Board Members and Executives Engage in Share Transactions

Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK900.00...

Deutsche Bank  Keeps Their Buy Rating on Novo Nordisk (0QIU)

In a report released today, Elmar Kraus from DZ BANK AG maintained a Hold rating on Novo Nordisk (0QIU – Research Report). The company's shares clo...

DZ BANK AG Sticks to Their Hold Rating for Novo Nordisk (0QIU)

Hims & Hers Health down as Super Bowl ad draws controversy

JPMorgan lowered the firm's price target on Novo Nordisk (NVO) to DKK 1,000 from DKK 1,050 and keeps an Overweight rating on the shares. Published ...

Novo Nordisk price target lowered to DKK 1,000 from DKK 1,050 at JPMorgan

Eli Lilly Q4 Earnings: Now The Magical $1 Trillion Dollar Market Cap Is In Sight

Kepler Capital analyst David Evans maintained a Hold rating on Novo Nordisk (0QIU – Research Report) on February 5 and set a price target of DKK715...

Kepler Capital  Remains a Hold on Novo Nordisk (0QIU)

Eli Lilly Q4: Don't Miss Out On 2025 Gains, There's Limited Space Left

HIMS

NONOF

Screenshot 2024-11-20 at 6.30.30 PM

BRTX

BioRestorative Ends Q3 In &#39;Strong&#39; Financial Position, Reports Positive Data For Its Phase 2 BRTX-100 Chronic Back Pain Trial

Screenshot 2024-09-10 at 4.29.40 PM

Armed With Its Patent Portfolio, BioRestorative Therapies Has Success In The Laboratory And At The Negotiating Table: Is Profitability Close Behind?

Screenshot 2024-08-22 at 5.32.58 PM

RDHL

RedHill&#39;s Opaganib Shows Diabetes And Obesity Potential With Positive In Vivo Results

Screenshot 2024-06-18 at 1.15.14 AM

BioRestorative Therapies Enters Preclinical Assessment Of Its Patented Stem-Cell Technology Prior To First-In-Human Studies

Screenshot 2024-05-16 at 5.52.00 PM

ELAB

Elevai Labs (NASDAQ: ELAB) Acquires Rights To Develop Muscle Loss Prevention Assets For Anticipated Use In Anti-Obesity Treatments, Launches Two New Subsidiaries

Screenshot 2024-02-22 at 11.51.01 PM

BTTX

Better Therapeutics Follows Up Wins Including FDA Authorization For AspyreRx In 2023 With Securing FDA Breakthrough Device Designation Targeting Advanced Liver Disease

Press Releases

NVO CLASS ACTION ALERT: BFA Law Alerts Novo Nordisk Investors that the Company has been Sued for Fraud – Contact BFA Law by March 25 Class Action Deadline (NYSE:NVO)

Legal

Lowey Dannenberg Notifies Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $200,000 in Losses to Contact the Firm

INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Lawsuit Against Novo Nordisk A/S - NVO

NVO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Novo Nordisk A/S Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit

Shareholder Rights Law Firm Robbins LLP Urges NVO Shareholders with Large Losses to Seek Counsel for the Novo Nordisk A/S Class Action

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Cardlytics, Novo Nordisk, Micron, and ModivCare and Encourages Investors to Contact the Firm

The Gross Law Firm Notifies Novo Nordisk A/S Investors of a Class Action Lawsuit and Upcoming Deadline - NVO

NVO DEADLINE APPROACHING: BFA Law Notifies Novo Nordisk Investors to Contact the Firm before the Upcoming March 25 Class Action Deadline (NYSE:NVO)

Investors who lost money on Novo Nordisk A/S (NVO) should contact The Gross Law Firm about pending Class Action - NVO

Comments

Novo Nordisk

매도 수량

Novo Nordisk (NYSE:NVO) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌